(firstQuint)A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.

.

 Cohorts of 16 patients receive 1 of 2 doses of Ro 31-8959 for 20 weeks.

 Administration of the higher dose will proceed only after 2-week safety data for the first eight patients on the lower dose has been reviewed.

.

 A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.

@highlight

To investigate the toxicity, antiviral activity, and pharmacokinetics in HIV-infected patients receiving 16 weeks of oral saquinavir mesylate ( Ro 31-8959 ) at one of two doses.

